A hybrid technique of intracavitary and interstitial brachytherapy for locally advanced cervical cancer: initial outcomes of a single-institute experience
Naoya Murakami,
Kazuma Kobayashi,
Satoshi Shima,
Keisuke Tsuchida,
Tairo Kashihara,
Nikolaos Tselis,
Rei Umezawa,
Kana Takahashi,
Koji Inaba,
Yoshinori Ito,
Hiroshi Igaki,
Yuko Nakayama,
Koji Masui,
Ken Yoshida,
Tomoyasu Kato,
Jun Itami
Affiliations
Naoya Murakami
Department of Radiation Oncology, National Cancer Center Hospital
Kazuma Kobayashi
Department of Radiation Oncology, National Cancer Center Hospital
Satoshi Shima
Department of Radiation Oncology, National Cancer Center Hospital
Keisuke Tsuchida
Department of Radiation Oncology, National Cancer Center Hospital
Tairo Kashihara
Department of Radiation Oncology, National Cancer Center Hospital
Nikolaos Tselis
Department of Radiotherapy and Oncology, Goethe-University Frankfurt
Rei Umezawa
Department of Radiation Oncology, National Cancer Center Hospital
Kana Takahashi
Department of Radiation Oncology, National Cancer Center Hospital
Koji Inaba
Department of Radiation Oncology, National Cancer Center Hospital
Yoshinori Ito
Department of Radiation Oncology, National Cancer Center Hospital
Hiroshi Igaki
Department of Radiation Oncology, National Cancer Center Hospital
Yuko Nakayama
Department of Radiation Oncology, National Cancer Center Hospital
Koji Masui
Department of Radiology, Kyoto Prefectural University of Medicine
Ken Yoshida
Department of Radiology, Osaka Medical College
Tomoyasu Kato
Department of Gynecologic Oncology, National Cancer Center Hospital
Jun Itami
Department of Radiation Oncology, National Cancer Center Hospital
Abstract Background Locally advanced uterine cervical cancer (LAUCC) with lateral tumor extension may not always be covered adequately by conventional intracavitary brachytherapy (ICBT). Hybrid intracavitary and interstitial brachytherapy (HBT) seems to be an effective alternative by improving anatomy-oriented dose optimisation. The purpose of this study was to report initial clinical result for LAUCC treated by HBT. Methods Between January 2012 and November 2015, 42 patients with LAUCC (T1b2-4a) were treated with primary radiation therapy including HBT. Patients with distant metastasis other than para-aortic lymph node spread were excluded from this study. A retrospective analysis was performed for toxicity evaluation and oncological outcome calculation. Results Median follow-up was 23.2 months (range 13.2–71.4). Two-year overall survival, progression free survival, and local control rate were 81.6, 54.4, and 80.2%, respectively. Seven patients experienced local recurrence (16.6%). Of those, five were confined to the uterus and two at the parametria. Late adverse events ≥ grade 3 were seen in 3 patients. Conclusions HBT can generate favorable local control in tumors which cannot be adequately covered by ICBT.